This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Delaugerre, C.
Right arrow Articles by Calvez, V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Delaugerre, C.
Right arrow Articles by Calvez, V.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, March 2001, p. 946-948, Vol. 45, No. 3
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.3.946-948.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

Prevalence and Conditions of Selection of E44D/A and V118I Human Immunodeficiency Virus Type 1 Reverse Transcriptase Mutations in Clinical Practice

Constance Delaugerre,1 Mireille Mouroux,1 Anne Yvon-Groussin,1 Anne Simon,2 Francis Angleraud,1 Jean-Marie Huraux,1 Henri Agut,1 Christine Katlama,3 and Vincent Calvez1,*

Departments of Virology,1 Internal Medicine,2 and Infectious Diseases,3 Pitié-Salpêtrière Hospital, Paris, France

Received 8 August 2000/Returned for modification 11 October 2000/Accepted 30 November 2000

Recently, it has been shown that a new mutational pattern (the E44D/A and/or V118I mutation) confers moderate phenotypic lamivudine resistance in the absence of the M184V mutation. The E44D/A and/or the V118I mutation does not exist in drug-naive patients, and the prevalence increases with the number of treatment regimens and lamivudine experience. The mutations can preexist in nucleoside-experienced but lamivudine-naive patients. They are always associated with zidovudine resistance-associated mutations, even in the absence of M184V. These mutations are more stable than the M184V substitution during antiretroviral treatment interruptions.

* Corresponding author. Mailing address: Department of Virology, 83, Blvd. de l'hôpital, 75013 Paris, France. Phone: 33142177401. Fax: 33142177411. E-mail: vincent.calvez{at}psl.ap-hop-paris.fr.

Antimicrobial Agents and Chemotherapy, March 2001, p. 946-948, Vol. 45, No. 3
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.3.946-948.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Turner, D., Brenner, B., Wainberg, M. A. (2004). Relationships among various nucleoside resistance-conferring mutations in the reverse transcriptase of HIV-1. J Antimicrob Chemother 53: 53-57 [Abstract] [Full Text]  
  • Girouard, M., Diallo, K., Marchand, B., McCormick, S., Gotte, M. (2003). Mutations E44D and V118I in the Reverse Transcriptase of HIV-1 Play Distinct Mechanistic Roles in Dual Resistance to AZT and 3TC. J. Biol. Chem. 278: 34403-34410 [Abstract] [Full Text]  
  • Stoeckli, T. C., MaWhinney, S., Uy, J., Duan, C., Lu, J., Shugarts, D., Kuritzkes, D. R. (2002). Phenotypic and Genotypic Analysis of Biologically Cloned Human Immunodeficiency Virus Type 1 Isolates from Patients Treated with Zidovudine and Lamivudine. Antimicrob. Agents Chemother. 46: 4000-4003 [Abstract] [Full Text]  
  • Shafer, R. W. (2002). Genotypic Testing for Human Immunodeficiency Virus Type 1 Drug Resistance. Clin. Microbiol. Rev. 15: 247-277 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»